Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer

Fig. 8

The associationS of LDHA and PGAM1 expression with bevacizumab response in ovarian cancer patients. a, b Bevacizumab conferred no significant improvements in OS for patients with both low LDHA expression (a) () and high LDHA expression (b) (). c Bevacizumab conferred significant improvements in OS for patients with low PGAM1 expression (HR: 0.34, 95%CI: 0.12–0.94, Log-rank P = 0.037). d Patients with high PGAM1 expression didn’t benefit from bevacizumab treatment significantly (HR: 0.80, 95%CI: 0.52–1.24, Log-rank P = 0.325)

Back to article page